Navigation Links
Sinovac to Host Conference Call to Report Third Quarter 2011 Unaudited Financial Results
Date:11/7/2011

BEIJING, Nov. 7, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of vaccines in China, today announced that it will release its unaudited financial results for the third quarter ended September 30, 2011 before market open on Monday, November 14, 2011. The Company will host a conference call on Monday, November 14, 2011 at 8:00 a.m. EST (November 14, 2011 at 9:00 pm China Standard Time) to review the Company's financial results and provide an update on recent corporate developments.

To access the conference call, please dial 1-877-407-4018 (USA) or 1-201-689-8471 (international). A replay of the call will be available from 11 a.m. EST on November 14, 2011 to November 28, 2011 at midnight. To access the replay, please dial 1-877-870-5176 (USA) or 1-858-384-5517 (international) and reference the replay pin number 382617.

A live audio webcast of the call will also be available from the Investors section on the corporate web site at www.sinovac.com. A webcast replay can be accessed on the corporate website beginning November 14, 2011 and the replay will remain available for 30 days.

About SinovacSinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases including hepatitis A, seasonal influenza, H5N1 (bird flu) pandemic influenza and H1N1 influenza. In 2009, Sinovac was the first company worldwide to receive approval for its H1N1 influenza vaccine, PANFLU.1, and has received orders from the Chinese Central Government pursuit to the government stockpiling program. The Company is developing a number of new vaccine products, including vaccines for pneumococcal conjugate, enterovirus 71 (EV71) (against Hand, Foot & Mouth Disease), pneumococcal polysaccharides, human rabies, HIB, rotavirus and epidemic meningitis, chickenpox and mumps & rubella. Its wholly owned subsidiary, Tangshan Yian, is focusing on the research, development, manufacturing and commercialization of animal vaccines, and has launched its internally developed inactivated rabies vaccine in China.

Safe Harbor StatementThis announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward-looking statements. Statements that are not historical facts, including statements about Sinovac's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement. Sinovac does not undertake any obligation to update any forward-looking statement, except as required under applicable law.Helen Yang/Chris LeeSinovac Biotech Ltd.Tel: +86-10-8279-9871/9659Fax: +86-10-6296-6910Email: ir@sinovac.com Investors:Stephanie CarringtonThe Ruth GroupTel: +1-646-536-7017Email: scarrington@theruthgroup.com MediaVictoria AguiarThe Ruth GroupTel: +1-646-536-7013Email: vaguiar@theruthgroup.com
'/>"/>

SOURCE Sinovac Biotech Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Sinovac Reports Unaudited Second Quarter 2011 Financial Results
2. Sinovac Announces Management Changes
3. Sinovac Holds 2011 Annual Shareholders Meeting
4. Sinovac Appoints Kenneth Lee to Board of Directors
5. Sinovac Reports Positive Phase I Clinical Trial Results for EV71 Vaccine Candidate Against Hand, Foot & Mouth Disease(HFMD)
6. Sinovac Reports Unaudited First Quarter 2011 Financial Results
7. Sinovac Presents at Two Investor Conferences in May 2011
8. Sinovac Files Annual Report on Form 20-F
9. Sinovac Participates in UBS Greater China Healthcare Corporate Day
10. Sinovac Reports Positive Preliminary Phase I Clinical Trial Results for EV71 Vaccine in Adult Group
11. Sinovac Biotech Submits Clinical Trial Application to SFDA for Pneumococcal Conjugate Vaccine (PCV)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... Dec. 6, 2016   AlloSource , one ... bone, skin and soft-tissue allografts for use in ... Process Manager, for being named to the Board ... Quality Award by the Commerce Department,s National Institute ... commitment to process excellence. The Baldrige Award is ...
(Date:12/6/2016)... , Dec. 6, 2016   ... clinical-stage medical dermatology and aesthetics company, today ... privately held specialty pharmaceutical company focused on ... skin conditions, including psoriasis, atopic dermatitis and ... agreement, Sienna will make an undisclosed upfront ...
(Date:12/6/2016)... 6, 2016  Blueprint Medicines Corporation (NASDAQ: ... kinase medicines for patients with genomically defined diseases, today ... of $125,000,000 million in shares of its common stock. ... a 30-day option to purchase up to an additional ... in connection with the public offering. All shares of ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... December 07, 2016 , ... Sharon Kleyne, host of the nationally syndicated radio ... on Voice of America, declared on her radio program in November 2016 the need ... when these bullies attack leaders in corporate America, they are trying to take advantage ...
(Date:12/7/2016)... ... December 07, 2016 , ... 1105 Media’s Live ... the Folio: Marketing Awards competition. Live From won in the Use of Social ... and ultimately successful projects undertaken by the media industry’s most innovative marketing professionals. ...
(Date:12/7/2016)... ... December 07, 2016 , ... Maureen McLaughlin, LA.c., a ... Medicine Associates of Connecticut (RMACT). McLaughlin brings nearly 20 years of experience with ... help patients realize their family building goals. Acupuncture helps fertility patients ...
(Date:12/7/2016)... NORFOLK, Va. (Dec. 3, 2016) , ... (PRWEB) ... ... the nation’s only patient advocacy nonprofit for individuals impacted by cerebral cavernous angiomas, ... work in New Mexico with a patient engagement program. New Mexico has more ...
(Date:12/6/2016)... ... December 06, 2016 , ... People ... can be seen on a type of MRI, according to a study appearing ... of the central nervous system characterized by tremors or trembling and stiffness in ...
Breaking Medicine News(10 mins):